基于数据挖掘探析祝光礼治疗冠心病经皮冠状动脉介入术后用药规律

Medication rule of Zhu Guangli after percutaneous coronary intervention for coronary heart disease:A study based on data mining

目的:基于数据挖掘方法探析祝光礼教授治疗冠心病经皮冠状动脉介入(PCI)术后的用药规律。方法:收集2022年6月1日至2022年9月30日杭州市中医院心血管科门诊及病房由祝教授治疗的冠心病PCI术后病案,利用古今医案云平台2.3.7对经筛选后的中药处方进行药物频次、性味归经和功效统计,对高频药物进行关联分析、聚类分析。结果:通过数据筛选,共纳入中药处方137首,涉及中药245味,使用频次≥25次的药物有22味,药性以温、平、微寒为主,药味以甘、辛、苦为主,归经以肺、脾、心经为主;功效以补虚、理气、活血化瘀等多见。关联分析得到10组常用药对、4种常见证型,以分组距离≥130为界,聚类分析得出丹香枳橘方、参芪玉芍方2个核心处方。结论:祝教授治疗冠心病PCI术后注重平调阴阳,以虚实为基本辨治要点,主张以丹香枳橘方治疗PCI术后实证患者,以参芪玉芍方治疗PCI术后虚证患者。

Objective:To investigate the medication rule of Professor Zhu Guangli after percutaneous coronary intervention(PCI)for coronary heart disease based on data mining.Methods:The cases of coronary heart disease after PCI treated by Professor Zhu were collected from the outpatient service and ward of Department of Cardiology,Hangzhou Hospital of Traditional Chinese Medicine,from June 1,2022 to September 30,2022.Cloud Platform of Ancient and Modern Medical Records 2.3.7 was used to analyze traditional Chinese medicine(TCM)prescriptions after screening in terms of drug frequency,nature/taste,meridian entry,and function,and association analysis and cluster analysis were performed for high-frequency drugs.Results:After data screening,137 TCM prescriptions were included,involving 245 TCM drugs.There were 22 drugs with a frequency of use of≥25 times.The drugs mainly had a warm,neutral or slightly cold nature and a sweet,pungent or bitter taste,and they mainly entered the lung,spleen,and heart meridians.The drugs had the main function of tonifying deficiency,regulating Qi,activating blood,and resolving stasis.The association analysis obtained 10 commonly used drug combinations and 4 common syndrome types,and with a grouping interval of≥130,the cluster analysis obtained two core prescriptions of Danxiang Zhiju prescription and Shenqi Yushao prescription.Conclusion:In the treatment of coronary heart disease after PCI,Professor Zhu focuses on the regulation of Yin and Yang,with deficiency and excess as the key points in syndrome differentiation-based treatment,and Professor Zhu proposes Danxiang Zhiju prescription for the treatment of patients with excess syndrome after PCI and Shenqi Yushao prescription for the treatment of patients with deficiency syndrome after PCI.